MaxCyte (MXCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of three nominees as Class II directors: Patrick J. Balthrop, Cynthia Collins, and Stanley C. Erck for the board.
Ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Audit Committee has selected CohnReznick LLP as the independent auditor for the upcoming fiscal year.
Shareholders are asked to ratify this selection at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MaxCyte
- Scalable cell engineering platform drives recurring revenue and supports a robust clinical pipeline.MXCT
Corporate presentation - Q2 2026 revenue fell 15%, but net loss narrowed and guidance and cash outlook were reaffirmed.MXCT
Q2 2026 - Q1 2026 revenue fell 7%, net loss narrowed, and a $10M share repurchase was authorized.MXCT
Q1 2026 - Election of directors and auditor ratification highlight governance and compensation practices.MXCT
Proxy filing - Restructuring, SecureDx integration, and new launches set the stage for global growth in 2026.MXCT
Stephens Annual Investment Conference - Electroporation and SPL growth drive strong momentum in cell and gene therapy markets.MXCT
Stifel 2024 Healthcare Conference - Q3 revenue rose 2% to $8.2M, core revenue up 23%, and six new SPLs set a record.MXCT
Q3 2024 - Q2 2024 revenue up 15% to $10.4M, SPL revenue surged 279%, and cash guidance raised to $180M.MXCT
Q2 2024 - Q1 2025 revenue fell 8% to $10.4M, but core business grew and guidance is reaffirmed.MXCT
Q1 2025 - 2025 guidance targets 8–15% core revenue growth and $5M SPL revenue, leveraging SeQure Dx.MXCT
Q4 2024